Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.46 |
| ▸ | HTR7 | P34969 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6645998 | 1.00 | PARP1 (0.62) | PARP1HRH3LOXL2PARP2HTR7 | |
| SCHEMBL6646614 | 0.99 | PARP1 (0.60) | PARP1HRH3LOXL2PARP2HTR7 | |
| SCHEMBL6645634 | 0.92 | HRH3 (0.65) | PARP1HRH3LOXL2HTR2AAPAF1 | |
| SCHEMBL6648629 | 0.92 | HRH3 (0.65) | PARP1HRH3LOXL2HTR2AAPAF1 | |
| SCHEMBL6643929 | 0.90 | HRH3 (0.67) | PARP1HRH3LOXL2HTR2AAPAF1 | |
| SCHEMBL6646824 | 0.88 | HRH4 (0.49) | PARP1HRH3LOXL2PARP2HTR7 | |
| SCHEMBL6645402 | 0.83 | LOXL2 (0.55) | PARP1HRH3LOXL2LMNAAPAF1 | |
| SCHEMBL6646518 | 0.83 | LOXL2 (0.55) | PARP1HRH3LOXL2LMNAAPAF1 | |
| SCHEMBL6649322 | 0.82 | PARP1 (0.57) | PARP1HRH3PARP2 | |
| SCHEMBL6644297 | 0.81 | PARP1 (0.58) | PARP1HRH3PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | claimed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | claimed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | PARP1 2/4885HRH3 2016/4885LOXL2 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.